The impact of genetic variations on the treatment of early rheumatoid...( Characterized by inflammation in the co...)

Characterized by inflammation in the connective tissues of the joints, rheumatoid arthritis (RA) can be a painful, crippling autoimmune disease. Traditionally, patients have been treated with disease-modifying antirheumatic drugs, or DMARDs, such as methotrexate (MTX). Several new therapies, however, focus on blocking tumor necrosis factor, or TNF, one of the body's chemical messengers with a role in regulating the inflammation. Although MTX and TNF blockers work well in the treatment of RA, they vary widely with regard to effectiveness and side effects, and there are currently no markers to predict response to particular drugs.

In a recent study, published in the September 2004 issue of Arthritis & Rheumatism, researchers set out to examine whether specific genetic variations could predict the response to treatment of early RA. Led by S. Louis Bridges, Jr., M.D., Ph.D. of the University of Alabama at Birmingham and Lindsey A. Criswell, M.D., M.P.H. of the University of California, San Francisco, the group analyzed genetic and clinical data on 457 patients in the early stages of RA who participated in a clinical trial comparing weekly methotrexate, 10 milligrams twice weekly of the anti-TNF drug etanercept, and 25 milligrams of etanercept twice weekly (the currently approved dose for RA). The results of this clinical trial have been previously published (Bathon et al. New Engl J Med 343:1586-1593, 2000).

Researchers examined patients for a particular genetic marker in the HLA region associated with susceptibility to RA (the so-called shared epitope), as well as genetic variants in the TNF gene region. Results of genetic testing were then correlated with treatment responses. Among patients treated with standard-dose etanercept, those with two copies of the shared epitope were four times more likely to achieve 50 percent improvement in disease activity (according to the criteria of the American College of Rheumatology) at 12 mon
'"/>

Contact: Amy Molnar
amolnar@wiley.com
201-748-8844
John Wiley & Sons, Inc.
9-Sep-2004

Page: 1 2
Related biology news :

1. Evidence for the impact of climate change on deep-sea biodiversity
2. Study shows impact of emotionally healthy fathers when mothers poor mental health affects children
3. Ocean scientists assess impact of seismic pulses in effort to protect whales
4. Joslin Diabetes Center releases new low impact exercise video
5. Noisy genes can have big impact
6. Trial found no impact of Malarone(TM) on performance and alertness tasks
7. Citizens asked to monitor impact of invasive bird species
8. Conservation International & SC Johnson invest in Ecuadors rainforest to offset climate impacts
9. Plant pathologists: Rust disease impacting ornamental plant production
10. K-State professor to give paper on potential impact of ag bioterrorism
11. Exxon Valdez oil spill impacts lasting far longer than expected, scientists say